Innovative approach for nasal drug delivery system for brain target
DOI:
https://doi.org/10.30574/gscarr.2021.9.3.0296Keywords:
Nose, Brain, Blood-brain barrier, Brain target, Nasal drug deliveryAbstract
The goal of brain drug targeting technology is the delivery of therapeutics across the blood brain barrier (BBB), including the human BBB. Nose to brain drug delivery has received a great deal of attention as a non- invasive, convenient and reliable drug delivery system. For the systemic and targetedadministration of drug. The various drug deliveries through some drug transport pathways, Factor influencing nasal drug absorption, formulation strategies nose to brain, colloidal carriers in nose to brain drug delivery system and nasal delivery systems. Physiological barriers (BBB) that restricts the delivery of drug to CNS. Thus intranasal route has attracted a wide attention of convenient, non-invasive, reliable, and safe route to achieve faster and higher level of drug in the brain through olfactory region by passing blood brain barrier. Intranasal administration rapid onset of action, no first –pass effect , no gastrointestinal degradation lungs toxicity and non-invasiveness application and also improves bioavailability.
Metrics
References
Lisbeth Illum.Nasal drug delivery—possibilities, problems and solutions. Journal of Controlled Release. 2003; 87: 187–198.
Sachin Chhajed, Sagar Sangale, SD Barhate. Advantageous Nasal Drug Delivery System: A Review. International Journal of Pharmaceutical Sciences and Research.
Jayant Rai, Preeti Yadav, Aashal Shah, ND Kantharia. Brain targeted drug delivery system: An overview of recent developments and challenges. Pharmaceutical Summit and Expo October 08-10. 2015.
Illum L.Drug delivery systems for nasal application. In: Hýncal AA, Kas HS, Sumnu M, editors. Third International Pharmaceutical Technology Symposium [Proceedings].
Garcia-Garcia E, Andrieux, K, Gil S, Couvreur P.Colloidal carriersand blood–brain barrier (BBB)translocation: Awayto deliver drugs to the brain. Int. J. Pharm. 2005; 298: 274–292.
Illum L. Transport of drugs from the nasal cavity to the central nervous system: Eur J Pharm Sci. 2011; 11: 1-18.
Sivilotti L, Nistri A. GABA receptor mechanisms in the central nervous system: Prog Neurobiol. 1991; 2(1): 35–92.
PShabana, BrahmaiahBonthagarala, Abbaraju Lakshmi Harini, Varun Dasari. Nasal Drug Delivery: A Potential Route for Brain Targeting, International Journal of Advances in Scientific Research. 2015; 65-70.
Abdur Rauf Khan, Mengrui Liu, Muhammad Wasim Khan, Guangxi Zhai. Progress in brain targeting drug delivery system by nasal route. Journal of Controlled Release. 2017; 364-389.
Soni V, Chorasia MK,Gupta Y, Jain A,Kohli DV, Jain SK. Novel approaches fo rdrug delivery to the brain: Indian J. Pharm. Sci. 2004; 66(2): 711-720.
Water beemd H, Camenisch G, Folkers G, Chretien JR, Raevsky O. Estimation of blood brain barrier crossing of drugs using molecular size and shape, and H bonding descriptors: J. Drug Targeting. 1998; 6(2): 151-165.
Begley DJ. The blood–brain barrier: principles for targeting peptides and drugs to the central nervous system: J. Pharm. Pharmacol. 1996; 48: 136–146.
Begley DJ. The blood–brain barrier: principles for targeting peptides and drugs to the central nervous system: J.Pharm. Pharmacol. 1996; 48: 136–146.
Garcia Garcia E, Andrieux, K, Gil S, Couvreur P. Colloidalcarriersandblood–brainbarrier (BBB)translocation:Awaytodeliverdrugs to the brain. Int. J. Pharm. 2005; 298: 274–292.
Arslan FB, OzturkAtar K, Calis S. Antibody-mediated drug delivery. Int J Pharm. 2021 Mar 1; 596: 120268.
Wang JZ, Xiao N, Zhang YZ, Zhao CX, Guo XH, Lu LM. Mfsd2a-based pharmacological strategies for drug delivery across the blood-brain barrier.
Chin SH, Burm JS, Kim YW. Selective dermal rejuvenation using intradermal injection of carbon dioxide and hyaluronic acid for facial wrinkles. Ann Plast Surg. Jun 2013; 70(6): 628-31.
Chin SH, Burm JS, Kim YW. Selective dermal rejuvenation using intradermal injection of carbon dioxide and hyaluronic acid for facial wrinkles. Ann Plast Surg. Jun 2013; 70(6): 628-31.
Christoph Bitter, Katja Suter- Zimmermann, Christian Surber. Nasal Drug Delivery in Humans. 2011; 40: 20–35.
Satish BalakrishnaBhise, AdhikraoVyankatrao Yadav, Amelia MakrandAvachat, RajkumarMalayandi. Bioavailability of intranasal drug delivery system. Asian Journal of Pharmaceutics – October-December 2008.
Brem H, et al. Placebo controlled trial of safety and efficacy of intraoperative controlled delivery by biodegradable polymers of chemotherapy for recurrentgliomas: The Lancet. 1995; 3(2): 1008-1012.
MParvathi. Intranasal drug delivery to brain:an overview.International Journal of Research in Pharmacy and Chemistry. 2012; 2231-2781.
Tushar K.Vyas, AliasgarShahiwala, SudhanvaMarathe and AmbikanandanMisra. Intranasal Drug Delivery for Brain Targeting. Current Drug Delivery. 2005; 165-175.
MacKay JA, Deen DF, Szoka Jr. FC. Distribution in brain liposomes after convection enhanced delivery; modulation by particle charge, particle diameter and presence of steric. Coating Brain Res. 2005; 1035: 129-135.
Mahoney MJ, Saltman WM. Controlled release of proteins to tissue transplants for treatments of neurodegenerative disorders: J Pharm Sci. 1996; 85(2): 1276-1281.
Benoit JP, Faisant N, Venier-Julienne MC, Menei P. Development of microsphplications.JControl Release, 65(2), 2000, 285-291. Applications J Control Release. 2000; 65(2): 285-291.
Downloads
Published
How to Cite
Issue
Section
License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
